BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  ITUS Corporation Licenses CAR-T Technology From the Wistar Institute

  ITUS has formed a subsidiary, Certainty Therapeutics, to develop and commercialize the innovative CAR-T technology.

  November 14, 2017

   · 

  5 min read
• Drug Development

  Medicenna Presents Clinical Data From Previous Phase I and II Clinical Trials of MDNA55

  The poster presentation by Dr. Bexon provides an overview of the safety and efficacy results from previous Phase I and II clinical trials of the targeted immunotherapy, MDNA55, in 66 patients with recurrent glioblastoma, the most common and deadly form of brain cancer.

  November 14, 2017

   · 

  4 min read
• Business

  Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights

  As of September 30, 2017, Pluristem had $21.3 million in cash and cash equivalents, bank deposits, restricted deposits and marketable securities.

  November 14, 2017

   · 

  7 min read
• Business

  Deciphera Pharmaceuticals Announces Third Quarter 2017 Financial Results and Corporate Highlights

  As of September 30, 2017, Deciphera Pharmaceuticals reported cash and cash equivalents of $82.1 million.

  November 14, 2017

   · 

  10 min read
• American Academy of Ophthalmology Release: Stem Cell Therapy Shows Promise for Common Cause of Blindness

  Results from two early clinical trials show that it may be possible to use human embryonic stem cells as treatment for the dry form of macular degeneration, according to presentations given today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

  November 14, 2017

   · 

  4 min read
• 

  Biotech Bay

  Bay Area’s EBR Systems Scores $50M to Complete Global Heart Failure Trial

  The financing was led by Australian private equity firms M.H. Carnegie & Co. and Brandon Capital Partners.

  November 14, 2017

   · 

  5 min read
• Business

  Arlington Capital Partners Announces Majority Investment in Grand River Aseptic Manufacturing

  Based in Grand Rapids, MI, GRAM is a leading contract, development and manufacturing organization (“CDMO”) focused on the development, manufacture and finishing of parenteral pharmaceuticals.

  November 14, 2017

   · 

  3 min read
• 

  FDA

  Roche Wins FDA Nod for the VENTANA MMR IHC Panel for Patients Diagnosed With Colorectal Cancer

  The tests detect certain proteins associated with a DNA repair mechanism called MMR, and aid in differentiating between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer.

  November 14, 2017

   · 

  5 min read
• ProQR Prices Approximately $20M Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

  In addition, in the public offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares at the public offering price, less underwriting discounts and commissions.

  November 14, 2017

   · 

  4 min read
• Business

  Strongbridge Biopharma plc Provides Corporate Update and Reports Third Quarter 2017 Financial Results

  For the three months ended September 30, 2017, basic and diluted net loss attributable to ordinary shareholders on a GAAP basis was $35.1 million, or $0.98 per share.

  November 14, 2017

   · 

  20 min read